Key stats
Market capitalization
28.819MUSD
Dividends yield (FY)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−1.03USD
About Unicycive Therapeutics, Inc
ISIN
US90466Y1038
Sector
Commercial Services
Website
unicycive.com
CEO
Shalabh Gupta
Headquarters
Los Altos
Employees
9
Founded
2016
Unicycive Therapeutics, Inc. engages in the development of treatment for kidney diseases. Its products include UNI-494, Renazorb, and UNI-220. The company was founded by Shalabh Gupta on August 18, 2016 and is headquartered in Los Altos, CA.
Income Statement
Balance Sheet
Cash Flow
Earnings
Next:—
0
Revenue
0